>No fun for COR longs today, but perhaps a buying opportunity.<
Provided you think the company still has credibility.
What if there is no bona fide interest in CX-717 and the ampakine platform by Big Pharma and all the talk about a pending deal is just… talk? If that’s the case, the stock still has a lot of room to fall, IMO.
How about the Rodman/Renshaw "Top Picks" release on August 22,2007, hyping COR with a target price of $4.50? Do you think R&R didn't know this deal was in the works? What a scumbag outfit.
Market Data 
Markets 
AI
